Optimal interventional treatment for liver cancer: HAIC, TACE or iTACE?

• DOI: 10.1016/j.jimed.2023.03.001
• Publication Date: 2023-05-02T21:18:37Z
• Authors: Naijian Ge; Hongbo Wang; Chengjian He; Xiangdong Wang; Jian Huang; Yefa Yang
• Keywords: Transcatheter arterial chemoembolization; Liver Cancer; Interventional radiology; Hepatocellular cancer

Primary liver cancer is a common and lethal malignancy in China. Transcatheter arterial chemoembolization (TACE) globally recognized as the preferred treatment modality for non-surgical resection of hepatocellular carcinoma (HCC), while transcatheter infusion (TAI) another effective interventional HCC. In recent years, hepatic chemotherapy (HAIC) has gained increasing attention an application-regulated TAI. Owing to current debate medical community regarding use HAIC TACE HCC, application both approaches should be considered at higher level, with broader perspective more normative aspect. Accordingly, we aimed define rational combination TAI/HAIC (iTACE), which suggests that two interventions are not superior but lead mutually beneficial situation. this review, sought discuss development, specification, application, challenge innovation, debate, union TACE, clinical latest research on iTACE. We introduce new concepts iTACE expect breakthroughs owing combined major tools.